[go: up one dir, main page]

NO20053762L - Kondensert furanforbindelse. - Google Patents

Kondensert furanforbindelse.

Info

Publication number
NO20053762L
NO20053762L NO20053762A NO20053762A NO20053762L NO 20053762 L NO20053762 L NO 20053762L NO 20053762 A NO20053762 A NO 20053762A NO 20053762 A NO20053762 A NO 20053762A NO 20053762 L NO20053762 L NO 20053762L
Authority
NO
Norway
Prior art keywords
represents hydrogen
furan compound
compound
condensed furan
condensed
Prior art date
Application number
NO20053762A
Other languages
English (en)
Other versions
NO20053762D0 (no
Inventor
Takayuki Kawaguchi
Jun Murakami
Hidenori Akatsuka
Toru Iijima
Takashi Mitsui
Tatsuya Watanabe
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of NO20053762D0 publication Critical patent/NO20053762D0/no
Publication of NO20053762L publication Critical patent/NO20053762L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Sammendrag Kondensert furanforbindelse med formel (I) : hvor ring X representerer benzen, pyridin etc.; Y representerer eventuelt substituert amino, sykloalkyl, aryl, mettet eller umettet, heterosyklisk gruppe; A representerer en enkelt-binding, lavere alkylen, alkenyliden eller alkenylen, eller oksygen; R1 representerer hydrogen, halogen etc.; R3 representerer hydrogen etc.; og R4 representerer hydrogen etc.; eller et farmakologisk akseptabelt salt av forbindelsen. Forbindelsene er anvendelige som medisin, spesielt som inhibitor mot aktivert blodkoagulasjonsfaktor X.
NO20053762A 2003-01-09 2005-08-08 Kondensert furanforbindelse. NO20053762L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003003536 2003-01-09
JP2003334598A JP2005104838A (ja) 2003-01-09 2003-09-26 縮合フラン化合物
PCT/JP2004/000074 WO2004063202A1 (ja) 2003-01-09 2004-01-08 縮合フラン化合物

Publications (2)

Publication Number Publication Date
NO20053762D0 NO20053762D0 (no) 2005-08-08
NO20053762L true NO20053762L (no) 2005-10-07

Family

ID=32716377

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053762A NO20053762L (no) 2003-01-09 2005-08-08 Kondensert furanforbindelse.

Country Status (19)

Country Link
US (2) US7514449B2 (no)
EP (1) EP1582521A4 (no)
JP (2) JP2005104838A (no)
KR (2) KR100827263B1 (no)
CN (1) CN100344632C (no)
AR (1) AR042827A1 (no)
AU (1) AU2004204003B2 (no)
BR (1) BRPI0406721A (no)
CA (1) CA2510519C (no)
IL (1) IL169193A0 (no)
MX (1) MXPA05007408A (no)
MY (1) MY139461A (no)
NO (1) NO20053762L (no)
NZ (1) NZ541198A (no)
PL (1) PL378249A1 (no)
RU (1) RU2302422C2 (no)
TW (1) TWI328588B (no)
WO (1) WO2004063202A1 (no)
ZA (1) ZA200504972B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312345B (en) * 2003-06-30 2009-07-21 Mitsubishi Tanabe Pharma Corp Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives
TW200512181A (en) * 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
TW200524915A (en) 2003-09-26 2005-08-01 Tanabe Seiyaku Co Carbamoyl-type benzofuran derivatives
JP4710445B2 (ja) * 2004-07-08 2011-06-29 田辺三菱製薬株式会社 医薬組成物
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006083003A1 (ja) * 2005-02-02 2006-08-10 Ajinomoto Co., Inc. 新規ベンズアミジン化合物
JP2006298909A (ja) * 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd 医薬組成物
JPWO2006137350A1 (ja) * 2005-06-22 2009-01-15 キッセイ薬品工業株式会社 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CN100376582C (zh) * 2006-04-26 2008-03-26 浙江大学 一种六氢呋喃[3,2-c]喹啉衍生物的制备方法
WO2008024725A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
CA2660963A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
TW200900408A (en) * 2007-03-02 2009-01-01 Kyowa Hakko Kogyo Kk Fused pyridine derivative
US20100173828A1 (en) * 2008-07-25 2010-07-08 Abbott Gmbh & Co. Kg Aß(X - 38 .. 43) oligomers, and processes, compositions, and uses thereof
RU2396267C1 (ru) * 2009-03-03 2010-08-10 Южный научный центр Российской академии наук (ЮНЦ РАН) 4-ЗАМЕЩЕННЫЕ-3-(1-АЛКИЛ-2-ХЛОР-1Н-ИНДОЛ-3-ИЛ)ФУРАН-2,5-ДИОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ДЛЯ ФОТОХИМИЧЕСКОГО ГЕНЕРИРОВАНИЯ СТАБИЛЬНЫХ ФЛУОРЕСЦИРУЮЩИХ СОЕДИНЕНИЙ И (4,5-ЗАМЕЩЕННЫЕ-6-АЛКИЛ-1Н-ФУРО[3,4-c]КАРБАЗОЛ-1,3(6Н)-ДИОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ФЛУОРОФОРОВ
CN102675230A (zh) * 2012-05-17 2012-09-19 盛世泰科生物医药技术(苏州)有限公司 一种3-氨基-2-氰基-6-溴吡嗪的制备方法
CN104981472A (zh) * 2012-11-08 2015-10-14 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途
US9933880B2 (en) * 2014-03-17 2018-04-03 Tactual Labs Co. Orthogonal signaling touch user, hand and object discrimination systems and methods
CN107405319A (zh) * 2014-11-03 2017-11-28 希罗姆波尔蒂克斯有限责任公司 抗纤维蛋白溶解化合物
TW201733985A (zh) * 2016-02-29 2017-10-01 陶氏農業科學公司 用於製備4-烷氧基-3-羥基吡啶甲酸之方法
CN111417640B (zh) * 2017-11-03 2024-04-05 蒙特利尔大学 化合物及其在干细胞和/或祖细胞扩增中的应用
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
CN115747298B (zh) * 2022-10-10 2023-10-27 浙江大学 昆虫烟酰胺酶抑制剂及鉴定方法及用于杀虫剂的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU926914A1 (ru) * 1980-05-26 1992-04-23 Научно-исследовательский институт фармакологии АМН СССР Производные 1,2,3,4-тетрагидробензофуро[3,2-с]-пиридина или хлоргидрат, обладающие р дом свойств анальгетиков и антагонистов морфина
JPS61218589A (ja) * 1985-03-26 1986-09-29 Eisai Co Ltd ５―（６―イミダゾ〔１，２―ａ〕ピリジニル）ピリジン誘導体
WO1994017075A1 (en) 1993-01-20 1994-08-04 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Diazepin derivatives and antiviral compositions
CN1131418A (zh) * 1994-06-06 1996-09-18 株式会社绿十字 新型稠环羧酸化合物或其盐及其医药用途
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FR2761072B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
GB9711126D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Cyanoamidines
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
CN1186324C (zh) * 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
AU2001277731A1 (en) 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
AU2003221178B2 (en) 2002-03-28 2006-06-15 Tanabe Seiyaku Co., Ltd. Benzofuran derivative
CA2494091C (en) * 2002-08-02 2011-02-01 Richard B. Toupence Substituted furo [2,3-b| pyridine derivatives
EP1678168B1 (en) 2003-10-24 2012-07-11 Exelixis, Inc. P70s6 kinase modulators and method of use

Also Published As

Publication number Publication date
NZ541198A (en) 2008-01-31
BRPI0406721A (pt) 2005-12-20
AU2004204003A1 (en) 2004-07-29
KR20050091081A (ko) 2005-09-14
NO20053762D0 (no) 2005-08-08
TW200413385A (en) 2004-08-01
MXPA05007408A (es) 2005-09-12
CN100344632C (zh) 2007-10-24
US7514449B2 (en) 2009-04-07
KR20070094818A (ko) 2007-09-21
RU2005125204A (ru) 2006-01-27
US20060094724A1 (en) 2006-05-04
WO2004063202A1 (ja) 2004-07-29
PL378249A1 (pl) 2006-03-20
RU2302422C2 (ru) 2007-07-10
AU2004204003B2 (en) 2007-03-29
JP2005104838A (ja) 2005-04-21
EP1582521A1 (en) 2005-10-05
AR042827A1 (es) 2005-07-06
CA2510519C (en) 2010-03-16
MY139461A (en) 2009-10-30
CA2510519A1 (en) 2004-07-29
JP4310437B2 (ja) 2009-08-12
US7737161B2 (en) 2010-06-15
TWI328588B (en) 2010-08-11
IL169193A0 (en) 2007-07-04
CN1723210A (zh) 2006-01-18
KR100827263B1 (ko) 2008-05-07
US20090156803A1 (en) 2009-06-18
EP1582521A4 (en) 2007-09-19
ZA200504972B (en) 2006-04-26
JPWO2004063202A1 (ja) 2006-05-18

Similar Documents

Publication Publication Date Title
NO20053762L (no) Kondensert furanforbindelse.
NO20072605L (no) Nytt antranilinsyrederivat eller et salt derav
NO20060220L (no) Forbindelser med inhiberene aktivitet mot natriumavhengige transportorer
ATE366724T1 (de) Kondensierte heterocyclische derivate
EA200601235A1 (ru) Производные тиазола
EP1637521A4 (en) NEW TRICYCLIC HETEROCYCLIC COMPOUND
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
NO20076006L (no) Acetylenderivater
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
EP1669352A4 (en) THIAZOLINE DERIVATIVE AND ITS USE
EP1564213A4 (en) IMIDAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF
DK0976748T3 (da) Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
ATE337318T1 (de) Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
DE60329189D1 (de) Pyrrolidinderivate als oxytocin antagonisten
NO20061831L (no) Benzofuranderivater av karbamoyltype
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
EP1254907A4 (en) Pyrrolopyridazine CONNECTIONS
TW200616679A (en) Modified-release preparation
ATE478884T1 (de) Oligosaccharidderivat
MY151167A (en) Benzimidazole compound
NO20054020L (no) Medisin for forhindring og behandling av arterosklerose og hypertensjon
MY148804A (en) Heteroarylcarbamoylbenzene derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application